Oncogenicity of DNA in vivo: Tumor induction with expression plasmids for activated H-ras and c-myc
Abstract
All vaccines and other biological products contain contaminating residual DNA derived from the production cell substrate. Whether this residual cell-substrate DNA can induce tumors in vaccine recipients and thus represent a risk factor has been debated for over 50 years without resolution. As a first step in resolving this issue, we have generated expression plasmids for the activated human H-ras oncogene and for the murine c-myc proto-oncogene. Their oncogenic activity was confirmed in vitro using the focus-formation transformation assay. Two strains of adult and newborn immune-competent mice were inoculated with different amounts of either plasmid alone or with a combination of the H-ras and c-myc plasmids. Tumors developed only in mice inoculated with both plasmids and only at the highest amount of DNA (12.5 microg of each plasmid). The NIH Swiss mouse was more sensitive than the C57BL/6 mouse, and newborn animals were more sensitive than adults. Cell lines were established from the tumors. PCR and Southern hybridization analyses demonstrated that both inoculated oncogenes were present in all of the tumor-derived cell lines and that the cells in the tumors were clonal. Western analysis demonstrated that both oncoproteins were expressed in these cell lines. These results demonstrate that cellular oncogenes can induce tumors following subcutaneous inoculation. Such information provides a possible way of evaluating and estimating the theoretical oncogenic risk posed by residu…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High-passage Vero cell DNA has potential tumorigenicity.
“due to the potential tumorigenicity of high-passage Vero cell DNA and the fact that residual host cell DNA (HCD) cannot be completely removed during the vaccine production process [5,6,7]”
From Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine (2024) · cites this paper as [5]
Residual host cell DNA cannot be completely removed during the vaccine production process.
“due to the potential tumorigenicity of high-passage Vero cell DNA and the fact that residual host cell DNA (HCD) cannot be completely removed during the vaccine production process [5,6,7]”
From Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine (2024) · cites this paper as [5]
Cites
Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells
Yew, N. S., Wysokenski, D. M., Wang, K. X., Ziegler, R. J., Marshall, J., McNeilly, D., Cherry, M., Osburn, W., & Cheng, S. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-575 · Cited by 113 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219 · see citing works
Establishing acceptable limits of residual DNA.
Yang, H. (2013) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2013.00910 · Cited by 60 · see citing works
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27 · see citing works
Li, J., Pan, R., Yue, F., Gao, T., Wu, X., Shi, L., Wang, Y., Zhao, D., Lan, Z., Chen, H., et al. (2024) · Vaccines · doi:10.3390/vaccines12121379 · Cited by 8 · see citing works
- Authors
- Sheng, L., Cai, F., Zhu, Y., Pal, A., Athanasiou, M., Orrison, B., Blair, D. G., Hughes, S. H., Coffin, J. M., Lewis, A. M., & Peden, K.
- Affiliations
- Center for Biologics Evaluation and Research (US)
- Frederick National Laboratory for Cancer Research (US)
- Tufts University (US)
- Corresponding author
- Peden, Keith
- Venue
- Biologicals
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 36
- Issue
- 3
- Pages
- 184-197
- ISSN
- 1045-1056 (ISSN-L)
- OpenAlex
- W1966441576
- Cited by
- 35
- References
- 1
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 3 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2014: 6 · 2013: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biologicals (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA089441)
- National Institute of Allergy and Infectious Diseases
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- oncogenicity, H-ras oncogene, c-myc proto-oncogene, tumor induction, expression plasmids, vaccine safety, neonatal mice, cancer cell lines, clonality, oncoprotein expression
- MeSH terms
- Proto-Oncogene Mas, Animals, DNA, Mice, Inbred C57BL, Models, Biological, Neoplasm Transplantation, Neoplasms, Oligonucleotides, Plasmids, Risk Factors, Proto-Oncogene Proteins c-myc, ras Proteins, Cancer Vaccines, NIH 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review